# A Study of BGM0504 in Early T2DM With Obesity

Study · id `cardio:ct-nct07743983` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07743983](<https://clinicaltrials.gov/study/NCT07743983>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07743983

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 372 participants.

## Technical summary

Registry record NCT07743983. Randomized; no masking; primary purpose treatment. Start 2026-09-17 (actual); primary completion 2028-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 372 participants (planned count; ClinicalTrials.gov record NCT07743983, source copy `cardio:ctgov-nct07743983-2026-10-13`, retrieved 2026-10-26)
- Started: 2026-09-17 (actual) (ClinicalTrials.gov record NCT07743983, source copy `cardio:ctgov-nct07743983-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2028-09-30 (anticipated) (ClinicalTrials.gov record NCT07743983, source copy `cardio:ctgov-nct07743983-2026-10-13`, retrieved 2026-10-26)
- Completion: 2028-11-30 (anticipated) (ClinicalTrials.gov record NCT07743983, source copy `cardio:ctgov-nct07743983-2026-10-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07743983, source copy `cardio:ctgov-nct07743983-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07743983-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of BGM0504 in Early T2DM With Obesity
- Condition: Type 2 Diabetes (T2DM)
- Intervention (Drug): BGM0504
- Intervention (Drug): semaglutide
- Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: BrightGene Bio-Medical Technology Co., Ltd. (`cardio:org-brightgene-bio-medical-technology-co-ltd`)

## Provenance

Content hash: 6e4454f8f5bb4678f0027795ae48d185e92f5c92706435aa6513e3c8be1581e8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
